Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancer

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Anbalagan, Muralidharan ^a   Moroz, Krzysztof ^a   Ali, Alaa ^a   Carrier, Latonya ^a   Glodowski, Seth ^a   Rowan, Brian G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; PROTEIN TYROSINE KINASE; ESTROGEN RECEPTOR; PARAFFIN;

ADULT; AFRICAN AMERICAN; AGE; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CAUCASIAN; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; ETHNIC DIFFERENCE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; BREAST TUMOR; CELL FRACTIONATION; ENZYMOLOGY; ETHNOLOGY; METABOLISM; MIDDLE AGED; NEGRO;

AFRICAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MIDDLE AGED; PARAFFIN EMBEDDING; RECEPTORS, ESTROGEN; SRC-FAMILY KINASES; SUBCELLULAR FRACTIONS;

EID: 84858741454     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033017     Document Type: Article

References (41)

1. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, et al. (2007) Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 110: 876-884.
2. Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, et al. (2009) Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 11: R18.
3. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, et al. (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24: 5652-5657.
4. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, et al. (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434.
5. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, et al. (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659-2671.
6. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, et al. (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334.
7. Cleator S, Heller W, Coombes RC, (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8: 235-244.
8. Huang F, Reeves K, Han X, Fairchild C, Platero S, et al. (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67: 2226-2238.
9. Planas-Silva MD, Bruggeman RD, Grenko RT, Stanley Smith J, (2006) Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem Biophys Res Commun 341: 73-81.
10. Herynk MH, Beyer AR, Cui Y, Weiss H, Anderson E, et al. (2006) Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther 5: 3023-3031.
11. Bromann PA, Korkaya H, Courtneidge SA, (2004) The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 23: 7957-7968.
12. Guy CT, Muthuswamy SK, Cardiff RD, Soriano P, Muller WJ, (1994) Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev 8: 23-32.
13. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, et al. (2006) Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 97: 263-274.
14. Fincham VJ, Unlu M, Brunton VG, Pitts JD, Wyke JA, et al. (1996) Translocation of Src kinase to the cell periphery is mediated by the actin cytoskeleton under the control of the Rho family of small G proteins. J Cell Biol 135: 1551-1564.
15. Yeatman TJ, (2004) A renaissance for SRC. Nat Rev Cancer 4: 470-480.
16. Ingley E, (2008) Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta 1784: 56-65.
17. Bolos V, Gasent JM, Lopez-Tarruella S, Grande E, (2010) The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther 3: 83-97.
18. Frame MC, (2002) Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 1602: 114-130.
19. Acosta JJ, Munoz RM, Gonzalez L, Subtil-Rodriguez A, Dominguez-Caceres MA, et al. (2003) Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. Mol Endocrinol 17: 2268-2282.
20. Gonzalez L, Agullo-Ortuno MT, Garcia-Martinez JM, Calcabrini A, Gamallo C, et al. (2006) Role of c-Src in human MCF7 breast cancer cell tumorigenesis. J Biol Chem 281: 20851-20864.
21. Tan M, Li P, Sun M, Yin G, Yu D, (2006) Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene 25: 3286-3295.
22. Finn RS, (2008) Targeting Src in breast cancer. Ann Oncol 19: 1379-1386.
23. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767.
24. Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema JG, et al. (1996) c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 180: 383-388.
25. Reissig D, Clement J, Sanger J, Berndt A, Kosmehl H, et al. (2001) Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue. J Cancer Res Clin Oncol 127: 226-230.
26. Campbell EJ, McDuff E, Tatarov O, Tovey S, Brunton V, et al. (2008) Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. Br J Cancer 99: 1769-1774.
27. Elsberger B, Tan BA, Mitchell TJ, Brown SB, Mallon EA, et al. (2009) Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients? Am J Pathol 175: 1389-1397.
28. Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, et al. (2011) Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol.
29. Elsberger B, Fullerton R, Zino S, Jordan F, Mitchell TJ, et al. (2010) Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression. Br J Cancer 103: 899-909.
30. Kanomata N, Kurebayashi J, Kozuka Y, Sonoo H, Moriya T, (2011) Clinicopathological significance of Y416Src and Y527Src expression in breast cancer. J Clin Pathol 64: 578-586.
31. Jackson JG, Yoneda T, Clark GM, Yee D, (2000) Elevated levels of p66 Shc are found in breast cancer cell lines and primary tumors with high metastatic potential. Clin Cancer Res 6: 1135-1139.
32. Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE, et al. (2001) Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene 20: 1152-1163.
33. Mao W, Irby R, Coppola D, Fu L, Wloch M, et al. (1997) Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 15: 3083-3090.
34. Brower V, (2009) Search for new treatments intensifies for triple-negative breast cancer. J Natl Cancer Inst 101: 1536-1537.
35. Carey L, Winer E, Viale G, Cameron D, Gianni L, (2010) Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7: 683-692.
36. Gucalp A, Sparano JA, Caravelli J, Santamauro J, Patil S, et al. (2011) Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer. Clin Breast Cancer.
37. Zou D, Yoon HS, Anjomshoaa A, Perez D, Fukuzawa R, et al. (2009) Increased levels of active c-Src distinguish invasive from in situ lobular lesions. Breast Cancer Res 11: R45.
38. Zhang S, Huang WC, Li P, Guo H, Poh SB, et al. (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17: 461-469.
39. Anbalagan M, Carrier L, Glodowski S, Hangauer D, Shan B, et al. (2011) KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor alpha positive breast cancer. Breast Cancer Res Treat.
40. Maitra A, Ashfaq R, Gunn CR, Rahman A, Yeo CJ, et al. (2002) Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol 118: 194-201.
41. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, et al. (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206.